Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018.

Brunham LR, Ruel I, Aljenedil S, Rivière JB, Baass A, Tu JV, Mancini GBJ, Raggi P, Gupta M, Couture P, Pearson GJ, Bergeron J, Francis GA, McCrindle BW, Morrison K, St-Pierre J, Henderson M, Hegele RA, Genest J, Goguen J, Gaudet D, Paré G, Romney J, Ransom T, Bernard S, Katz P, Joy TR, Bewick D, Brophy J.

Can J Cardiol. 2018 Dec;34(12):1553-1563. doi: 10.1016/j.cjca.2018.09.005.

PMID:
30527143
2.

Canadian Cardiovascular Society position statement on familial hypercholesterolemia.

Primary Panel:, Genest J, Hegele RA, Bergeron J, Brophy J, Carpentier A, Couture P, Davignon J, Dufour R, Frohlich J, Gaudet D, Gupta M, Krisnamoorthy P, Mancini J, McCrindle B, Raggi P, Ruel I, St-Pierre J.

Can J Cardiol. 2014 Dec;30(12):1471-81. doi: 10.1016/j.cjca.2014.09.028. Epub 2014 Oct 2. Review.

4.

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.

Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K.

JAMA. 2016 Aug 16;316(7):743-53. doi: 10.1001/jama.2016.11004.

PMID:
27533159
5.

Familial Hypercholesterolemia: Advances in Recognition and Therapy.

Cartier JL, Goldberg AC.

Prog Cardiovasc Dis. 2016 Sep - Oct;59(2):125-134. doi: 10.1016/j.pcad.2016.07.006. Epub 2016 Jul 29. Review.

PMID:
27477957
6.

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr.

J Am Coll Cardiol. 2017 Oct 3;70(14):1785-1822. doi: 10.1016/j.jacc.2017.07.745. Epub 2017 Sep 5.

7.

Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.

Agabiti Rosei E, Salvetti M.

High Blood Press Cardiovasc Prev. 2016 Sep;23(3):217-30. doi: 10.1007/s40292-016-0155-2. Epub 2016 Aug 27. Review.

8.

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2013 Dec;34(45):3478-90a. doi: 10.1093/eurheartj/eht273. Epub 2013 Aug 15.

9.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com.

Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M, Zangeneh F, Bush MA.

Endocr Pract. 2017 Apr 2;23(4):479-497. doi: 10.4158/EP171764.GL. Epub 2017 Feb 3.

PMID:
28156151
10.

Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Lozano P, Henrikson NB, Dunn J, Morrison CC, Nguyen M, Blasi PR, Anderson ML, Whitlock E.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Aug.

11.

Severe xanthomatosis in heterozygous familial hypercholesterolemia.

Aljenedil S, Ruel I, Watters K, Genest J.

J Clin Lipidol. 2018 Jul - Aug;12(4):872-877. doi: 10.1016/j.jacl.2018.03.087. Epub 2018 Apr 3.

PMID:
29778561
12.

Cascade Screening for Familial Hypercholesterolemia (FH).

Ned RM, Sijbrands EJ.

PLoS Curr. 2011 May 23;3:RRN1238. doi: 10.1371/currents.RRN1238.

13.
14.

Prevalence and Predictors of Cholesterol Screening, Awareness, and Statin Treatment Among US Adults With Familial Hypercholesterolemia or Other Forms of Severe Dyslipidemia (1999-2014).

Bucholz EM, Rodday AM, Kolor K, Khoury MJ, de Ferranti SD.

Circulation. 2018 May 22;137(21):2218-2230. doi: 10.1161/CIRCULATIONAHA.117.032321. Epub 2018 Mar 26.

15.

Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management.

Mytilinaiou M, Kyrou I, Khan M, Grammatopoulos DK, Randeva HS.

Front Pharmacol. 2018 Jul 12;9:707. doi: 10.3389/fphar.2018.00707. eCollection 2018. Review.

16.

My Approach to the Patient With Familial Hypercholesterolemia.

Safarova MS, Kullo IJ.

Mayo Clin Proc. 2016 Jun;91(6):770-86. doi: 10.1016/j.mayocp.2016.04.013. Review.

17.

Management of Familial Hypercholesterolemia in Hong Kong.

Hu M, Hooper AJ, Bockxmeer FM, Watts GF, Chan JC, Tomlinson B.

J Atheroscler Thromb. 2016 May 2;23(5):520-31. doi: 10.5551/jat.34314. Epub 2016 Feb 12. Review.

18.

The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations.

De Castro-Orós I, Pocoví M, Civeira F.

Appl Clin Genet. 2010 Aug 5;3:53-64. Print 2010.

19.

New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials.

Ellis KL, Pang J, Schultz CJ, Watts GF.

Eur J Prev Cardiol. 2017 Jul;24(11):1200-1205. doi: 10.1177/2047487317708890. Epub 2017 May 9. Review.

PMID:
28482694
20.

[Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].

Cybulska B, Gaciong Z, Hoffman P, Jankowski P, Kłosiewicz-Latoszek L, Kaźmierczak J, Mitręga K, Opolski G, Pająk A, Ponikowski P, Rynkiewicz A, Stępińska J, Średniawa B, Kalarus Z.

Kardiol Pol. 2016;74(4):394-8. doi: 10.5603/KP.2016.0051. Polish.

PMID:
27098076

Supplemental Content

Support Center